Profile data is unavailable for this security.
About the company
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
- Revenue in USD (TTM)114.39m
- Net income in USD-494.28m
- Incorporated2021
- Employees999.00
- LocationAlvotech SA9, Rue De BitbourgLUXEMBOURG 1273LuxembourgLUX
- Websitehttps://www.alvotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 423.49m | -147.07m | 3.14bn | 517.00 | -- | 24.02 | -- | 7.41 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 3.18bn | 226.00 | -- | 51.56 | -- | 34.54 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -188.60m | 3.18bn | 251.00 | -- | 3.58 | -- | -- | -2.71 | -2.71 | 0.00 | 11.76 | 0.00 | -- | -- | 0.00 | -23.02 | -20.71 | -23.66 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Biohaven Ltd | 0.00 | -517.18m | 3.20bn | 239.00 | -- | 9.85 | -- | -- | -6.83 | -6.83 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -99.74 | -- | -123.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Denali Therapeutics Inc | 295.39m | -137.25m | 3.28bn | 375.00 | -- | 2.25 | -- | 11.11 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Ideaya Biosciences Inc | 15.50m | -128.89m | 3.38bn | 124.00 | -- | 3.25 | -- | 218.26 | -2.00 | -2.00 | 0.2416 | 12.51 | 0.0234 | -- | 64.20 | 125,032.30 | -19.44 | -19.17 | -20.27 | -21.05 | -- | -- | -831.35 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| TG Therapeutics Inc | 289.33m | 41.20m | 3.41bn | 284.00 | 100.14 | 21.32 | 82.48 | 11.79 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 35.47m | -470.79m | 3.48bn | 525.00 | -- | 7.19 | -- | 98.11 | -4.24 | -4.24 | 0.3189 | 3.90 | 0.0384 | -- | -- | 67,567.62 | -51.72 | -20.02 | -57.39 | -24.65 | -- | -- | -1,346.13 | -61.79 | -- | -80.00 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Arcellx Inc | 131.66m | -50.54m | 3.50bn | 130.00 | -- | 7.03 | -- | 26.62 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Alvotech SA | 114.39m | -494.28m | 3.62bn | 999.00 | -- | -- | -- | 31.62 | -2.05 | -2.05 | 0.4909 | -2.47 | 0.117 | 1.69 | 1.97 | 114,507.50 | -50.54 | -- | -63.82 | -- | -23.89 | -- | -432.09 | -- | 0.8107 | -1.26 | 2.49 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Guardant Health Inc | 603.73m | -460.90m | 3.98bn | 1.78k | -- | 58.05 | -- | 6.60 | -3.92 | -3.92 | 5.17 | 0.5607 | 0.3754 | 4.37 | 7.03 | 339,362.00 | -28.66 | -22.26 | -33.02 | -24.59 | 60.37 | 64.62 | -76.34 | -97.07 | 5.66 | -59.55 | 0.9435 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Ultragenyx Pharmaceutical Inc | 442.59m | -613.35m | 4.11bn | 1.28k | -- | 26.00 | -- | 9.28 | -8.02 | -8.02 | 5.75 | 1.69 | 0.329 | 1.61 | 6.18 | 346,854.20 | -45.59 | -33.35 | -55.09 | -38.30 | 88.59 | 93.13 | -138.58 | -154.71 | 2.28 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Dyne Therapeutics Inc | 0.00 | -257.40m | 4.11bn | 143.00 | -- | 7.56 | -- | -- | -3.97 | -3.97 | 0.00 | 5.49 | 0.00 | -- | -- | 0.00 | -63.48 | -52.81 | -67.12 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Alkermes Plc | 1.73bn | 599.95m | 4.16bn | 2.10k | 7.03 | 3.32 | 6.27 | 2.41 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Data as of Jul 23 2024. Currency figures normalised to Alvotech SA's reporting currency: US Dollar USD
5.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Oaktree Capital Management LPas of 31 Mar 2024 | 2.90m | 1.04% |
| Bracebridge Capital LLCas of 31 Mar 2024 | 2.71m | 0.97% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.41m | 0.86% |
| Sculptor Capital LPas of 31 Mar 2024 | 1.95m | 0.70% |
| Shinhan Securities Co., Ltd. (Private Banking)as of 31 Dec 2022 | 1.49m | 0.53% |
| IS Funds Ltd.as of 31 Dec 2022 | 1.24m | 0.45% |
| Littlejohn & Co. LLC (Investment Management)as of 31 Mar 2024 | 1.22m | 0.44% |
| Kvika eignast�ring hf.as of 31 Dec 2022 | 994.60k | 0.36% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 813.88k | 0.29% |
| Lodbrok Capital LLPas of 31 Mar 2024 | 751.41k | 0.27% |
More ▼
Data from 14 Mar 2024 - 04 Jul 2024Source: FactSet Research Systems Inc.
